ASP Isotopes Clears Key Hurdle in Renergen Deal with Shareholder Vote

Rhea-AI Filing Summary

On July 11, 2025, ASP Isotopes Inc. (NASDAQ: ASPI) filed a Form 8-K (Item 8.01) to disclose that shareholders of Renergen Limited have approved the scheme of arrangement for ASP Isotopes’ proposed acquisition. The approval eliminates a major condition precedent and materially advances the transaction toward closing. A press release describing the vote is attached as Exhibit 99.1 (the fifth and sixth paragraphs are expressly excluded from incorporation by reference).

The filing contains no purchase price, financing structure, or anticipated closing timetable, and it includes no additional financial statements under Item 9.01 beyond the press-release exhibit. Accordingly, the report functions primarily as a regulatory notice highlighting a positive milestone in ASP Isotopes’ M&A strategy rather than providing quantitative information.

Positive

• Renergen shareholders approved the scheme of arrangement, removing a principal obstacle to ASP Isotopes’ planned acquisition and increasing deal certainty.

Negative

• No financial terms or closing timetable were disclosed, leaving investors without clarity on cost, dilution, or expected synergies.

Insights

M&A Specialist

TL;DR: Renergen shareholder approval clears a key hurdle, materially reducing execution risk for ASP Isotopes’ acquisition.

The decisive vote by Renergen shareholders is a critical step in any scheme-of-arrangement transaction because it satisfies one of the most uncertain deal contingencies. With target-company shareholder consent now secured, remaining closing conditions are largely procedural—court sanction, regulatory clearances, and customary closing deliverables. From an investor perspective, this materially improves deal certainty and should narrow any merger-spread discount previously priced into ASPI shares. The filing’s lack of financial detail limits visibility on dilution, leverage, or expected synergies, but the directional signal is positive: execution risk is substantially lower today than yesterday.

0001921865false00019218652025-07-112025-07-11iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 11, 2025

ASP Isotopes Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41555		87-2618235
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

601 Pennsylvania Avenue NW South Building, Suite 900 Washington, DC		20004
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (202) 756-2245

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01		ASPI		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 8.01. Other Events.

On July 11, 2025, ASP Isotopes Inc. (the “Company”) issued a press release announcing the shareholders of Renergen Limited have approved the scheme of arrangement for the proposed acquisition by ASP Isotopes Inc.  A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference, other than the fifth and sixth paragraphs of the press release.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release, dated July 11, 2025, of ASP Isotopes Inc. announcing the shareholders of Renergen Limited have approved the scheme of arrangement for the proposed acquisition by ASP Isotopes Inc.
104		Cover Page Interactive Date File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASP ISOTOPES INC.
Date: July 11, 2025	By:	/s/ Paul Mann
	Name:	Paul Mann
	Title:	Chief Executive Officer

3

FAQ

What material event did ASP Isotopes (ASPI) report on July 11 2025?

The company reported that Renergen Limited shareholders approved the scheme of arrangement for ASP Isotopes’ proposed acquisition.

Did Renergen shareholders approve ASP Isotopes’ acquisition?

Yes. The Form 8-K states that Renergen Limited shareholders voted in favor of the scheme of arrangement.

Which exhibit contains details of the Renergen approval?

Exhibit 99.1 is the press release announcing the shareholder vote approval.

What is ASP Isotopes’ trading symbol and exchange?

The company’s common stock trades on Nasdaq under the symbol ASPI.

Were any financial statements included with this 8-K?

No. The filing only attaches the press release and an Inline XBRL cover page; no financial statements were provided.

Which section of the Exchange Act triggered this current report?

The report was filed under Section 13 or 15(d) of the Securities Exchange Act of 1934.